1000TiP Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies - Yarza, R.; Garralda, E.; Sánchez Perez, V.; De Velasco Oria, G.A.; Lorusso, P.M.; Rodríguez, R.M.; Kristeleit, R.S.; Ring, A.; Yap, C.; Rekowski, J.; Dickinson, P.; Ruston, L.; et al. (Annals of Oncology, 2025)